Ortiz-Urda S - Search Results

1

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600^E/K mutant advanced melanoma.

Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. Algazi AP, et al. Among authors: ortiz urda s. Pigment Cell Melanoma Res. 2019 Jul;32(4):603-606. doi: 10.1111/pcmr.12777. Epub 2019 Apr 13. Pigment Cell Melanoma Res. 2019. PMID: 30801911 No abstract available.

2

Cutting edge in medical management of cutaneous oncology.

Chong K, Daud A, Ortiz-Urda S, Arron ST; UCSF High Risk Skin Cancer Program. Chong K, et al. Semin Cutan Med Surg. 2012 Jun;31(2):140-9. doi: 10.1016/j.sder.2012.03.002. Semin Cutan Med Surg. 2012. PMID: 22640435 Free PMC article. Review.

3

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Posch C, et al. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19. Proc Natl Acad Sci U S A. 2013. PMID: 23431193 Free PMC article.

4

NRAS mutant melanoma--undrugable?

Posch C, Ortiz-Urda S. Posch C, et al. Oncotarget. 2013 Apr;4(4):494-5. doi: 10.18632/oncotarget.970. Oncotarget. 2013. PMID: 23660168 Free PMC article. Review.

5

The risk of melanoma in airline pilots and cabin crew: a meta-analysis.

Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver JE, Ortiz-Urda S. Sanlorenzo M, et al. JAMA Dermatol. 2015 Jan;151(1):51-8. doi: 10.1001/jamadermatol.2014.1077. JAMA Dermatol. 2015. PMID: 25188246 Free PMC article. Review.

6

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.

Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Curl P, et al. PLoS One. 2014 Sep 8;9(9):e107255. doi: 10.1371/journal.pone.0107255. eCollection 2014. PLoS One. 2014. PMID: 25198196 Free PMC article.

7

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.

Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. Vujic I, et al. Oncotarget. 2014 Sep 15;5(17):7936-44. doi: 10.18632/oncotarget.2326. Oncotarget. 2014. PMID: 25277205 Free PMC article.

8

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.

Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Sanlorenzo M, et al. J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16. J Am Acad Dermatol. 2014. PMID: 25440439 Free PMC article.

9

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.

Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Vujic I, et al. Oncotarget. 2015 Jan 20;6(2):969-78. doi: 10.18632/oncotarget.2824. Oncotarget. 2015. PMID: 25504439 Free PMC article.

10

The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes.

Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. Sanlorenzo M, et al. JAMA Dermatol. 2015 Apr;151(4):450-2. doi: 10.1001/jamadermatol.2014.4643. JAMA Dermatol. 2015. PMID: 25517516 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page